Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
Adaptive Biotechnologies (Nasdaq: ADPT) announced participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adaptive Biotechnologies (Nasdaq: ADPT) announced participation in two upcoming investor conferences. The company will host 1x1 meetings at the Craig-Hallum 23rd Annual Institutional Investor Conference on May 28 in Minneapolis and present at the William Blair 46th Annual Growth Stock Conference on June 3 at 3:20 p.m. Central Time.
A live and archived webcast of the William Blair presentation will be available in the Investors section of the company website.
Details
News Market Reaction – ADPT
On May 22, the first trading day after this news, ADPT closed 0.07% above the previous close.
Data tracked by StockTitan Argus for the May 22 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.
- Craig-Hallum 23rd Annual Institutional Investor Conference – Minneapolis, MN
Hosting 1x1 meetings on Thursday, May 28th - William Blair 46th Annual Growth Stock Conference – Chicago, IL
Presentation on Wednesday, June 3rd at 3:20 p.m. Central Time
Interested parties may access a live and archived webcast of the presentation from the William Blair Growth Stock Conference on the “Investors” section of the company website at: www.adaptivebiotech.com.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.